Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
argenx SE's Enterprise Value for the quarter that ended in Jun. 2026 was $52,884 Mil.
argenx SE's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,751 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE EV-to-EBIT Related Terms
argenx SE EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for argenx SE's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where argenx SE's EV-to-EBIT falls into.
argenx SE's current Enterprise Value is $47,551 Mil.
argenx SE's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,751 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a EV-to-EBIT of 27.15 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #254 out of 368 companies in the Biotechnology industry, placing it in the top 69%.
Is argenx SE's EV-to-EBIT too high?
argenx SE's current EV-to-EBIT is 27.15. The Biotechnology industry median EV-to-EBIT is 15.71. argenx SE's value of 27.15 is 72.8% above this industry median. Based on the distribution chart, argenx SE ranks #254 out of 368 companies in the Biotechnology industry, which is below the industry midpoint. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #254 out of 368 companies for EV-to-EBIT. This places argenx SE in the lower half of its industry. The industry median EV-to-EBIT is 15.71. argenx SE's value of 27.15 is 72.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.71, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current EV-to-EBIT of 27.15 is 72.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current EV-to-EBIT is 27.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,469.68, compared to a current price of $851.56 — trading 42.1% below its estimated fair value. The current EV-to-EBIT is 27.15 and 72.8% above the Biotechnology industry median of 15.71. argenx SE's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For argenx SE (ARGX), the current EV-to-EBIT is 27.15 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $851.56 is trading 42.1% below its estimated GF Value™ of $1,469.68.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
EV-to-EBIT: 27.15
GF Value™: $1,469.68 vs. price of $851.56 (42.1% below fair value)
Industry Position: 72.8% above the Biotechnology median (#254 of 368)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for ARGX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
